Conference Presentation Details - Overview
Targeted Therapy: Increasing Therapeutic Alternatives in Metastatic Breast Cancer
Release Date: March 27, 2009|
Expiration Date: March 27, 2010
Mar 5, 2009, Miami, FL
Lecture Overview
For today’s oncologists, the rapidly evolving area of targeted therapy for breast cancer leads to challenges in patient care and treatment decision making. For patients with ErbB2+ disease in the metastatic setting, disease progression following prior ErbB2-targeted therapy is common; several recent studies have addressed therapeutic options, such as utilization of small-molecule tyrosine kinase inhibitors with chemotherapy, combination regimens coupling 2 ErbB-targeted agents, or inhibitors of interrelated pathways, for this patient population. Another area of debate is treatment strategy selection for the frontline treatment of patients with ErbB2+ metastatic breast cancer. Traditionally, treatment options included an ErbB2-targeted agent with or without chemotherapy but recent studies have suggested that, for some patients, combining targeted therapy with a hormonal agent might be effective, while ongoing trials are examining the potential efficacy of all-biologic regimens combining ErbB2-directed and antiangiogenic agents. The Targeted Therapy: Increasing Therapeutic Alternatives in Metastatic Breast Cancer symposium will review and discuss the latest information on biologic therapies for ErbB2+ metastatic breast cancer. A presentation of relevant case studies and panel discussion will be used to illustrate current treatment recommendations and highlight newer therapeutic approaches as well as promote interaction and discussion about clinical issues that are still a matter of controversy.
This educational program is directed toward medical oncologists, surgeons, and radiation oncologists interested in the treatment of breast cancer. Physician assistants, research nurses, and fellows interested in the treatment of patients with breast cancer are also invited to participate.
Upon completion of this educational activity, you should be able to:
- Evaluate the use of biologic agents, including after progression on prior ErbB2-targeted therapy and as frontline therapy, in patients with advanced/metastatic ErbB2+ breast cancer
- Discuss the biologic rationale for and clinical efficacy and safety of combining ErbB-targeted agents with hormonal or antiangiogenic therapies for the treatment of metastatic breast cancer
- Incorporate data from clinical trials and current treatment recommendations concerning the combination of targeted therapies for patients with metastatic breast cancer into practice in order to improve treatment decision making
Instructions for Participation
- Read the following information before beginning the educational activity.
- Complete the Pretest.
- View and study all Flash video presentations.
- Complete the Posttest.
- Answer the evaluation questions.
- After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.
You will be permitted 2 attempts to successfully complete the Posttest.
Accreditation and Credit Designation
Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
You will be asked to login
or create an account.